UCB’s Speers to lead European Medicines Group
pharmafile | July 19, 2010 | Appointment | Sales and Marketing | European Medicines Group, UCB, appointment, sales and marketing
UCB Pharma’s managing director Matthew Speers has been elected chair of the European Medicines Group, taking over from Nigel Brooksby (Sanofi-Aventis).
Commenting on his appointment, Matthew Speers said: “Despite the tremendous advances in research and development we continue to face considerable market access challenges in the UK with uptake of innovative medicines still lagging significantly behind Europe.
“I am delighted to have been elected to lead the EMG and to continue the work we have undertaken to ensure that all UK citizens have timely access to appropriate, innovative medicines taking other countries in Europe as our benchmark.”
He will be supported by Lundbeck managing director Steve Turley, who has been elected vice-chair of the EMG.
Commenting on his appointment Steve Turley said: “The European perspective is an important one, as European healthcare systems tend to be founded on social values that are closely aligned with those of the NHS.
“We will continue to hold the mirror up to Europe and work together with government, clinicians and patients to improve the health and quality of life of people in the UK.”
Formed in 2001, the EMG focuses on access to medicines – an issue that remains as relevant today as it was nine years ago, the EMG said in a statement.
Working in partnership with the government, the NHS and the Association of the British Pharmaceutical Industry (ABPI), the EMG aims to help patients, carers and policy makers understand the contribution of the European pharmaceutical industry to the health and wealth of the UK.
Related Content
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
Rare and severe epilepsies – current treatments and advance therapeutics
The current forms of immunotherapy, how T cell therapy works and what the future holds
